June 7, 2019 10:59 AM EDT

Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma

Amber Tong

→ Otsuka has some good news to report on the other drug that it obtained in the $886 million acquisition of Astex Pharmaceuticals. ASTX727 combines …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ot­su­ka scores PhI­II win for an­oth­er As­tex drug; GSK ex­pands Nu­cala use in asth­ma

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma